Predict your next investment

Corporate Venture
HEALTHCARE | Pharmaceuticals / Drugs
sanofigenzymebioventures.com

See what CB Insights has to offer

Investments

25

Portfolio Exits

13

About Sanofi-Genzyme BioVentures

Sanofi-Genzyme Ventures is a corporate venture capital fund dedicated to helping Genzyme Corporation achieve its strategic goals. Founded in 2001, the $100 million fund has a current portfolio of direct corporate investments and has taken LP positions in funds managed by life-science focused VC firms. Through its direct investments in private early-stage companies, the fund aims to forge relationships which may lead to larger collaborations in the future. Genzyme Ventures is able to leverage the entire Genzyme organization, including its global experience and expertise in R&D, reimbursement, and commercialization, to provide portfolio companies with invaluable advice and assistance. Its Limited Partnership investments provide insight into the broader healthcare innovation landscape

Sanofi-Genzyme BioVentures Headquarter Location

500 Kendall Street

Cambridge, Massachusetts, 02142,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Sanofi-Genzyme BioVentures News

What GE Ventures, Sanofi-Genzyme BioVentures and Nexus Venture Partners won’t invest in

Oct 4, 2017

Shares1 A venture capital panel at Health 2.0 conference in Santa Clara, California, brought together corporate venture capitalists with a traditional VC who shared their pet peeves and what they wouldn’t invest in. First up Ruchita Sinha, senior director of investments at Sanofi-Genzyme BioVentures , the venture capital arm of drugmaker Sanofi. Sinha explained that she is less interested in technology and more in the actual problem that entrepreneurs are alleviating. “I have a personal pet peeve against Platform XYZ solution — you are a platform AI solution; you a platform blockchain solution. That’s great. Tell me what the problem you are solving,” she declared. “Personally, I am very much a paint point investor. I don’t care how you solve it, as long as you solve it. You can use whatever technology you want.” Sinha added a lot of entrepreneurs flip it around — start with the technology and then try to find a problem that could be addressed using that tech. And that, she implied, is a mistake. Seated next to Sinha was Iana Dimkova, director, GE Ventures who articulated that she wasn’t interested in b-to-c plays in healthcare. “While I do believe the consumerization of healthcare will happen, we’re not really looking at clinical products that are going directly to the consumer,” Dimkova said. “Unfortunately, there’s been a ton of money that’s been spent and so far there’s not really a business model to emulate. It turns out that most people really don’t want to pay for health out of pocket. It’s not something they look for. If they have a real issue, they still go to the doctor.” She added that eventually, she does believe “consumerization of healthcare will happen” but it’s not something GE Ventures is willing to bet on now. Seated next to Dimkova was Abhishek Sharma of Nexus Venture Partners , who is unattracted to business-to-business models in healthcare. “The entity or incumbent that [entrepreneurs] are selling to – their doors are sort of jammed,” he said. “You want them to open very fast but they won’t open that fast. More and more I am staying away from b-to-b startups that are selling to incumbents — payer, provider and any of those stakeholders.” Sharma explained that on the contrary, he wants to work with bright, ambitious entrepreneurs that are looking to turn current models of healthcare on their heads entirely. These three VCs have very different perspectives and maybe even be contradictory investment philosophies, but that essentially means entrepreneurs must do their homework before approaching investors. Photo: prachanart, Getty Images

Sanofi-Genzyme BioVentures Investments

25 Investments

Sanofi-Genzyme BioVentures has made 25 investments. Their latest investment was in Omada Health as part of their Series C - II on June 6, 2017.

CBI Logo

Sanofi-Genzyme BioVentures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/14/2017

Series C - II

Omada Health

$50M

Yes

2

4/26/2017

Series B - II

Evidation

$10M

Yes

2

4/25/2017

Series C

Science 37

$29M

No

2

10/18/2016

Series B

Subscribe to see more

$99M

Subscribe to see more

10

2/10/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/14/2017

4/26/2017

4/25/2017

10/18/2016

2/10/2016

Round

Series C - II

Series B - II

Series C

Series B

Series A

Company

Omada Health

Evidation

Science 37

Subscribe to see more

Subscribe to see more

Amount

$50M

$10M

$29M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

2

10

10

Sanofi-Genzyme BioVentures Portfolio Exits

13 Portfolio Exits

Sanofi-Genzyme BioVentures has 13 portfolio exits. Their latest portfolio exit was Science 37 on May 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/7/2021

Acq - Pending

$991

7

8/24/2020

Reverse Merger

8

3/29/2018

IPO

$991

3

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

5/7/2021

8/24/2020

3/29/2018

00/00/0000

00/00/0000

Exit

Acq - Pending

Reverse Merger

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

7

8

3

10

10

Sanofi-Genzyme BioVentures Acquisitions

3 Acquisitions

Sanofi-Genzyme BioVentures acquired 3 companies. Their latest acquisition was AnorMed on November 07, 2006.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/7/2006

Acquired

1

2/8/2005

Series D

Subscribe to see more

$99M

Subscribe to see more

10

5/31/1996

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/7/2006

2/8/2005

5/31/1996

Investment Stage

Series D

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

Total Funding

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Sanofi-Genzyme BioVentures Team

6 Team Members

Sanofi-Genzyme BioVentures has 6 team members, including current Senior Vice President, James P Sherblom.

Name

Work History

Title

Status

James P Sherblom

Senior Vice President

Current

Ann DeWitt

Senior Director

Current

Earl M Collier

Executive Vice President

Former

Jan van Heek

Executive Vice President

Former

Richard H Douglas

Senior Vice President

Former

Name

James P Sherblom

Ann DeWitt

Earl M Collier

Jan van Heek

Richard H Douglas

Work History

Title

Senior Vice President

Senior Director

Executive Vice President

Executive Vice President

Senior Vice President

Status

Current

Current

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.